Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) reported unaudited revenue of RMB3.35 billion for the three months ended 31 March 2026, marking a 5.30% year-on-year increase, according to a voluntary operational update released on 8 May 2026.

The medical device and pharma packaging segments delivered high single-digit revenue growth, making them the primary contributors to the top-line expansion. Orthopaedic and interventional products registered low single-digit increases, while the blood management business recorded a mid-single-digit decline.

Management emphasized that all figures are unaudited operational data and have not been reviewed by independent auditors. Investors are therefore urged to exercise caution when dealing in the Company’s securities.